On-target AEs management
Key physiological processes controlled by the TRK pathway include appetite, balance, and pain sensitivity. Consequently, TRK inhibitors are associated with a relatively unique set of on-target adverse events (AEs) that are unlike AEs seen with other anticancer therapies. These AEs remain under-recognized, and pain upon drug withdrawal has not been previously reported. As such, TRK-associated AEs warrant careful monitoring and management [1].
References
- Liu D, Flory J, Lin A, Offin M, Falcon CJ, Murciano-Goroff YR, Rosen E, Guo R, Basu E, Li BT, Harding JJ, Iyer G, Jhaveri K, Gounder MM, Shukla NN, Roberts SS, Glade-Bender J, Kaplanis L, Schram A, Hyman DM, Drilon A. Characterization of on-target adverse events caused by TRK inhibitor therapy. Ann Oncol. 2020; 31(9):1207-1215.
- Igel LI, Kumar RB, Saunders KH, Aronne LJ. Practical Use of Pharmacotherapy for Obesity. Gastroenterology 2017; 152: 1765–1779.
- Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015; 100: 342–362.
- Holst JJ. Incretin therapy for diabetes mellitus type 2. Curr Opin Endocrinol Diabetes Obes. 2020 Feb;27(1):2-10.
- Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol 2008; 7: 451–458.
- Cohen B, DeJong JM. Meclizine and placebo in treating vertigo of vestibular origin. Relative efficacy in a double-blind study. Arch Neurol 1972; 27: 129–135.
- Chobanian AV, Volicer L, Tifft CP et al. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med 1979; 301: 68–73.
- Davies IB, Bannister RG, Sever PS, Wilcox CS. Fludrocortisone in the treatment of postural hypotension: altered sensitivity to pressor agents [proceedings]. Br J Clin Pharmacol 1978; 6: 444P–445P.
- Lanier JB, Mote MB, Clay EC. Evaluation and management of orthostatic hypotension. Am Fam Physician 2011; 84: 527–536.